Some metastatic breast cancer data is not available. And some patients choose not to know it.
With the constant advancements in metastatic breast cancer, there are many situations where there may not be clear data on long-term outcomes or quality of life for certain drugs, said Patricia Jakel, MN, RN, AOCN.
Jakel is an advanced practice nurse at UCLA's solid tumor program, co-editor in chief of Oncology Nursing News, and a breast cancer survivor.
Transcription
We're leapfrogging so fast with metastatic breast cancer that we sometimes don't have data to tell you what it's going to be like in 4 or 5 years. That oftentimes is difficult for data-driven people. Other people, like myself, I didn't really want to know the data because I'm not a big data person. I want to know well what's the quality of life when you're on these medications? Am I going to be able to work? Am I going to be able to exercise? Exercise was important to me. So it really depends on what's important to you at that point in your life.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.